Regeneron Pharmaceuticals Valuation
Is REGN * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of REGN * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: REGN * (MX$15516) is trading below our estimate of fair value (MX$23447.98)
Significantly Below Fair Value: REGN * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for REGN *?
Other financial metrics that can be useful for relative valuation.
What is REGN *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$96.29b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 6.3x |
Enterprise Value/EBITDA | 17.8x |
PEG Ratio | 2.2x |
Price to Earnings Ratio vs Peers
How does REGN *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 63.1x | ||
CSL CSL | 34.7x | 14.7% | AU$133.7b |
GILD Gilead Sciences | 167.6x | 35.8% | US$81.3b |
VRTX Vertex Pharmaceuticals | 28x | 11.4% | US$101.5b |
AMGN Amgen | 21.9x | 9.0% | US$146.9b |
REGN * Regeneron Pharmaceuticals | 24.3x | 11.2% | Mex$96.3b |
Price-To-Earnings vs Peers: REGN * is good value based on its Price-To-Earnings Ratio (24.3x) compared to the peer average (63.2x).
Price to Earnings Ratio vs Industry
How does REGN *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Earnings vs Industry: REGN * is good value based on its Price-To-Earnings Ratio (24.3x) compared to the Global Biotechs industry average (31x).
Price to Earnings Ratio vs Fair Ratio
What is REGN *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 24.3x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate REGN *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$15,516.00 | Mex$17,668.16 +13.9% | 11.2% | Mex$20,236.78 | Mex$12,254.40 | n/a | 25 |
Apr ’25 | Mex$16,059.77 | Mex$17,057.15 +6.2% | 11.3% | Mex$19,757.17 | Mex$11,847.63 | n/a | 25 |
Mar ’25 | n/a | Mex$17,236.00 0% | 11.8% | Mex$20,206.85 | Mex$12,117.29 | n/a | 23 |
Feb ’25 | n/a | Mex$16,677.34 0% | 11.8% | Mex$19,375.31 | Mex$12,227.98 | n/a | 24 |
Jan ’25 | Mex$14,708.10 | Mex$15,555.30 +5.8% | 11.6% | Mex$19,026.34 | Mex$11,838.61 | n/a | 24 |
Dec ’24 | Mex$13,696.61 | Mex$15,612.08 +14.0% | 10.7% | Mex$18,317.18 | Mex$11,684.51 | n/a | 25 |
Nov ’24 | Mex$13,944.54 | Mex$16,156.05 +15.9% | 10.6% | Mex$19,050.07 | Mex$12,174.86 | n/a | 23 |
Oct ’24 | n/a | Mex$15,668.20 0% | 10.5% | Mex$18,302.55 | Mex$11,853.08 | n/a | 23 |
Sep ’24 | Mex$14,241.07 | Mex$15,231.89 +7.0% | 10.8% | Mex$17,857.67 | Mex$11,309.85 | n/a | 23 |
Aug ’24 | Mex$12,290.00 | Mex$14,521.49 +18.2% | 10.6% | Mex$17,690.91 | Mex$11,003.92 | n/a | 23 |
Jul ’24 | Mex$12,075.00 | Mex$14,735.40 +22.0% | 11.7% | Mex$17,845.67 | Mex$11,100.18 | n/a | 23 |
Jun ’24 | n/a | Mex$15,767.83 0% | 10.9% | Mex$18,733.37 | Mex$11,596.85 | n/a | 23 |
May ’24 | n/a | Mex$15,942.79 0% | 10.5% | Mex$18,871.32 | Mex$11,794.58 | Mex$15,516.00 | 23 |
Apr ’24 | Mex$14,649.91 | Mex$15,712.40 +7.3% | 10.9% | Mex$18,743.30 | Mex$11,714.56 | Mex$16,059.77 | 23 |
Mar ’24 | Mex$13,939.35 | Mex$15,249.76 +9.4% | 12.2% | Mex$18,557.81 | Mex$11,105.32 | n/a | 23 |
Feb ’24 | Mex$14,235.11 | Mex$15,142.66 +6.4% | 12.5% | Mex$19,200.89 | Mex$11,355.37 | n/a | 23 |
Jan ’24 | Mex$13,837.22 | Mex$15,858.58 +14.6% | 13.0% | Mex$20,331.93 | Mex$11,779.45 | Mex$14,708.10 | 23 |
Dec ’23 | Mex$14,292.70 | Mex$15,244.61 +6.7% | 13.3% | Mex$19,672.90 | Mex$11,014.53 | Mex$13,696.61 | 23 |
Nov ’23 | Mex$15,014.68 | Mex$15,470.74 +3.0% | 13.4% | Mex$20,309.76 | Mex$11,393.28 | Mex$13,944.54 | 23 |
Oct ’23 | Mex$14,080.53 | Mex$15,278.55 +8.5% | 11.2% | Mex$18,868.71 | Mex$11,729.20 | n/a | 22 |
Sep ’23 | Mex$11,985.67 | Mex$13,760.23 +14.8% | 10.7% | Mex$16,195.26 | Mex$10,905.35 | Mex$14,241.07 | 22 |
Aug ’23 | Mex$11,975.90 | Mex$13,793.13 +15.2% | 10.5% | Mex$16,165.93 | Mex$10,968.28 | Mex$12,290.00 | 22 |
Jul ’23 | Mex$12,030.00 | Mex$13,605.27 +13.1% | 11.5% | Mex$15,823.86 | Mex$10,736.19 | Mex$12,075.00 | 21 |
Jun ’23 | Mex$12,987.75 | Mex$13,755.18 +5.9% | 9.3% | Mex$15,710.73 | Mex$11,236.16 | n/a | 21 |
May ’23 | Mex$13,478.00 | Mex$13,707.45 +1.7% | 10.4% | Mex$15,619.38 | Mex$11,299.55 | n/a | 20 |
Analyst Forecast: Target price is less than 20% higher than the current share price.